Nanoimmunotherapy to treat ischaemic heart disease

Raphaël Duivenvoorden (Corresponding author), Max L. Senders, Mandy M.T. van Leent, Carlos Pérez-Medina, Matthias Nahrendorf, Zahi A. Fayad, Willem J.M. Mulder (Corresponding author)

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)

Abstract

Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalNature Reviews. Cardiology
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Myocardial Ischemia
Atherosclerosis
Inflammation
Lipids
Recurrence
Nanotechnology
Therapeutics
Interleukin-1
Chronic Disease
Cardiovascular Diseases
Arteries
Stroke
Myocardial Infarction
Cholesterol

Keywords

  • Animals
  • Anti-Inflammatory Agents/therapeutic use
  • Atherosclerosis/diagnosis
  • Humans
  • Immunity, Innate/drug effects
  • Immunotherapy/methods
  • Inflammation Mediators/antagonists & inhibitors
  • Molecular Targeted Therapy
  • Myocardial Ischemia/diagnosis
  • Nanomedicine/methods
  • Signal Transduction/drug effects

Cite this

Duivenvoorden, R., Senders, M. L., van Leent, M. M. T., Pérez-Medina, C., Nahrendorf, M., Fayad, Z. A., & Mulder, W. J. M. (2019). Nanoimmunotherapy to treat ischaemic heart disease. Nature Reviews. Cardiology, 16(1), 21-32. https://doi.org/10.1038/s41569-018-0073-1
Duivenvoorden, Raphaël ; Senders, Max L. ; van Leent, Mandy M.T. ; Pérez-Medina, Carlos ; Nahrendorf, Matthias ; Fayad, Zahi A. ; Mulder, Willem J.M. / Nanoimmunotherapy to treat ischaemic heart disease. In: Nature Reviews. Cardiology. 2019 ; Vol. 16, No. 1. pp. 21-32.
@article{4715b325fbf5404486d3c7d13c825590,
title = "Nanoimmunotherapy to treat ischaemic heart disease",
abstract = "Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.",
keywords = "Animals, Anti-Inflammatory Agents/therapeutic use, Atherosclerosis/diagnosis, Humans, Immunity, Innate/drug effects, Immunotherapy/methods, Inflammation Mediators/antagonists & inhibitors, Molecular Targeted Therapy, Myocardial Ischemia/diagnosis, Nanomedicine/methods, Signal Transduction/drug effects",
author = "Rapha{\"e}l Duivenvoorden and Senders, {Max L.} and {van Leent}, {Mandy M.T.} and Carlos P{\'e}rez-Medina and Matthias Nahrendorf and Fayad, {Zahi A.} and Mulder, {Willem J.M.}",
year = "2019",
month = "1",
doi = "10.1038/s41569-018-0073-1",
language = "English",
volume = "16",
pages = "21--32",
journal = "Nature Reviews. Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "1",

}

Duivenvoorden, R, Senders, ML, van Leent, MMT, Pérez-Medina, C, Nahrendorf, M, Fayad, ZA & Mulder, WJM 2019, 'Nanoimmunotherapy to treat ischaemic heart disease', Nature Reviews. Cardiology, vol. 16, no. 1, pp. 21-32. https://doi.org/10.1038/s41569-018-0073-1

Nanoimmunotherapy to treat ischaemic heart disease. / Duivenvoorden, Raphaël (Corresponding author); Senders, Max L.; van Leent, Mandy M.T.; Pérez-Medina, Carlos; Nahrendorf, Matthias; Fayad, Zahi A.; Mulder, Willem J.M. (Corresponding author).

In: Nature Reviews. Cardiology, Vol. 16, No. 1, 01.2019, p. 21-32.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Nanoimmunotherapy to treat ischaemic heart disease

AU - Duivenvoorden, Raphaël

AU - Senders, Max L.

AU - van Leent, Mandy M.T.

AU - Pérez-Medina, Carlos

AU - Nahrendorf, Matthias

AU - Fayad, Zahi A.

AU - Mulder, Willem J.M.

PY - 2019/1

Y1 - 2019/1

N2 - Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

AB - Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

KW - Animals

KW - Anti-Inflammatory Agents/therapeutic use

KW - Atherosclerosis/diagnosis

KW - Humans

KW - Immunity, Innate/drug effects

KW - Immunotherapy/methods

KW - Inflammation Mediators/antagonists & inhibitors

KW - Molecular Targeted Therapy

KW - Myocardial Ischemia/diagnosis

KW - Nanomedicine/methods

KW - Signal Transduction/drug effects

UR - http://www.scopus.com/inward/record.url?scp=85053403817&partnerID=8YFLogxK

U2 - 10.1038/s41569-018-0073-1

DO - 10.1038/s41569-018-0073-1

M3 - Review article

C2 - 30209355

AN - SCOPUS:85053403817

VL - 16

SP - 21

EP - 32

JO - Nature Reviews. Cardiology

JF - Nature Reviews. Cardiology

SN - 1759-5002

IS - 1

ER -

Duivenvoorden R, Senders ML, van Leent MMT, Pérez-Medina C, Nahrendorf M, Fayad ZA et al. Nanoimmunotherapy to treat ischaemic heart disease. Nature Reviews. Cardiology. 2019 Jan;16(1):21-32. https://doi.org/10.1038/s41569-018-0073-1